Clinical trials - Press Releases

Date	Title	Company
30-Jan-2020	Cynbiose receives €1.9 million ($2.1M) to launch CYNBIOME, preclinical excellence network on microbiome and infectious diseases	Cynbiose
30-Jan-2020	European Medicines Agency Validates Kite's Marketing Authorisation Application for Company's Second CAR T Cell Therapy	Kite
30-Jan-2020	Abcam Expands Cell Engineering Capabilities Through Asset Purchase of Applied StemCell’s Gene Editing Platform and Oncology Product Portfolio	ABCAM PLC
30-Jan-2020	REGULATORY ANNOUNCEMENT: Astellas Submits sNDA for Approval of Evrenzo® (roxadustat)	Astellas Pharma Inc.
30-Jan-2020	Sanofi: Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency	Sanofi
30-Jan-2020	FDA accepts for priority review Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis	Sanofi
30-Jan-2020	Autolus Announces Closing of Public Offering	Autolus Therapeutics plc
30-Jan-2020	Agilent Introduces New Cutting-Edge SureSelect DNA Kit	Agilent Technologies Inc.
30-Jan-2020	NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer	NuCana plc
30-Jan-2020	Bionetix, ProQinase, and Mercachemsyncom Announce a Joint Research Project from Target Identification to Clinical Study	Bionetix, ProQinase, and Mercachemsyncom
29-Jan-2020	Most innovative cancer drugs facing delays in reaching patients	The Institute of Cancer Research
29-Jan-2020	Sanofi : FDA accepts for priority review Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis	Sanofi
29-Jan-2020	Kite, a Gilead Company, to present latest cell therapy research at the 2nd European CAR T Cell Meeting, Sitges, Spain	Gilead
29-Jan-2020	SAGA Diagnostics Extends its Collaboration with Servier to Use Ultrasensitive SAGAsafe® Technology in Cancer Clinical Trials	LUND
29-Jan-2020	Immutep activities report - late-stage Phase IIb metastatic breast cancer results ETA, TACTI-002 results ETA	Immutep Limited
29-Jan-2020	Signant Health Enhances Audit Trail Reporting CapabiliTrialMax® to Improve eCOA Data Integrity Monitoring	Signant Health
28-Jan-2020	Registration Opens for SMi’s 20th Annual Pain Therapeutics Conference	SMi Group
24-Jan-2020	Dupixent®▼ (dupilumab), accepted for restricted use within NHS Wales for the treatment of moderate to severe atopic dermatitis in adolescents aged 12 years and over1	Sanofi
24-Jan-2020	Dupixent®▼ (dupilumab) available to treat adolescents with moderate to severe atopic dermatitis in Scotland1	Sanofi
24-Jan-2020	Sanofi Completes Acquisition of Synthorx, Inc.	Sanofi